A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 16-1970
More information available at ClinicalTrials.gov: NCT02723994
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers